Dallas-based Almaden Genomics—whose g.nome workflow platform aims to “democratize and accelerate bioinformatics by breaking down barriers in biotech R&D”—has launched a new Data Management and Informatics Services business to support its bioinformatics and computational biology solutions.

The company said the expansion underscores its commitment to advancing life sciences research by providing “innovative, scalable solutions that streamline data analysis and management” across multiple domains, including drug discovery, diagnostics, and biotech research.

“As we introduced our self-service, multi-omics analytics platform, making science accessible to all, we found that many companies still struggle with the upstream complexities of data ingestion, management and governance,” CEO David Gascoigne said in a statement. “Launching this new business aligns with our vision of transforming the bioinformatics landscape by making complex data management more accessible and actionable.”

Almaden was launched in October 2022 by venture development firm Catalyze Dallas Holdings.  The company was formerly part of IBM Research before becoming a standalone enterprise under Catalyze Dallas ownership

Aiming to serve researchers, pharmaceutical companies, and biotechs

Almaden cited the increasing complexity of biological data and the need for robust computational tools as drivers of its new service business—which aims to address “critical challenges” faced by researchers, pharmaceutical companies, and biotech organizations.

Per Almaden, key offerings of the new include:

Comprehensive Data Management: Almaden Genomics offers end-to-end bioinformatics solutions for managing and analyzing advanced multimodal real-world data. This includes support for high-throughput genomic, transcriptomic, clinical, and proteomic data, using “cutting-edge pipelines and algorithms.”

Cloud-Based Informatics Solutions: The new service provides “secure, scalable, and efficient” cloud solutions, enabling researchers to store, manage, and process large biological datasets in a customized environment.

Custom Bioinformatics Pipelines: Almaden Genomics specializes in designing and deploying custom bioinformatics pipelines tailored to specific research needs. Whether it’s genomic biomarker detection or aptamer discovery, the company’s solutions are said to deliver “accurate, real-time insights, powered by AI and machine learning.”

Data Quality and Governance: With data reliability as a top priority, Almaden’s new service focuses on data curation, harmonization, and governance, enabling researchers “to confidently rely on their data for critical decision-making.” The platform’s data catalog and integration tools help uncover hidden insights and ensure compliance with industry standards, Almaden said.

“By empowering researchers with the right data tools, we can accelerate the pace of discovery in drug development, biomarker research, and more,” Gascoigne added.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.